Meet the 2018 Laureates: Christos Mantzoros, MD, DSc

Mantzoros, Christos

Outstanding Clinical Investigator Award

Christos Mantzoros, MD, DSc

Christos Mantzoros, MD, DSC, an extraordinarily productive investigator, is currently the chief of the Nutrition Unit at Beth Israel Deaconess Medical Center and chief of the Endocrine Section at the VA Boston Healthcare System. Dr. Mantzoros serves as a full professor of medicine at Harvard Medical School and has served as a professor in environmental health at the School of Public Health. He is also the editor-in-chief of Metabolism (impact factor: 5.78).

He is a true innovator and a leader in the field of metabolism, as evidenced by the novel findings he has published, the novel compounds he has developed, the successful companies he has co-founded, and his excellent track record of funding over the past two decades. His translational work has elucidated the pharmacokinetics and physiology of leptin in humans and has contributed toward its approval by the FDA and other agencies internationally, has elucidated the role of adiponectin and the IGF system in malignancies, and has propelled forward the development of the insulin sensitizer CHRS-131, currently in Phase III clinical trials. Most recently, he has been studying the physiology of novel adipokines, myokines, and gastrointestinal tract-secreted hormones with potential implications in metabolic diseases. In addition, he has been advancing our understanding of the beneficial effects of Mediterranean diet through clinical epidemiology studies and by leading the translation of these discoveries to public health benefits through Pangea Inc., which he co-founded.

He is a true innovator and a leader in the field of metabolism, as evidenced by the novel findings he has published, the novel compounds he has developed, the successful companies he has co-founded, and his excellent track record of funding over the past two decades.

Dr. Mantzoros has published over 725 scientific articles in high-quality journals such as Nature, JCI, NEJM, including 190 peer-reviewed reviews and chapters. The reach and impact of his work is evidenced by the more than 28,200 citations (plus 5,000 citations from the Look Ahead Study) with an H index of 88 in Thompson Reuters and more than 46,000 citations with an H index of 112 in Google Scholar.

You may also like

  • Endocrine Society Celebrates Special Diabetes Program Extension

    The Endocrine Society applauds Congress for approving the first funding increase for the Special Diabetes Program in two decades. The U.S. Senate voted Friday March 8 to extend the program, which supports both diabetes care and research into type 1 diabetes, until the end of 2024. This is part of the six-bill package funding several…

  • New Position Statement Focuses on Patient Experience in Diabetes Care

    Healthcare providers who treat diabetes need to think beyond the clinical numbers, such as solely focusing on a person’s glucose goals. Taking the patient experience into account can improve the quality of care and facilitate attainment of treatment goals, according to a new position statement published in the Endocrine Society’s Journal of Clinical Endocrinology &…